Grant: $683,700 - National Institutes of Health - Sep. 29, 2009
No votes have been cast for this award yet
Award Description: The objective of this grant is to generate an effective vaccine against Hepatitis C virus, the major cause of liver cancer. Our vaccine platform is based on synthetic structures called peptoids that are selected by existing monoclonal antibodies that are already known neutralize the virus. These peptoids will be screened with these antibodies, and those that react will be coupled to carrier proteins and used to immunize mice. The mice should make antibodies that then both recognize both the peptoid and the virus.
Project Description: In this proposal we plan to use a panel of neutralizing monoclonal antibodies (MAbs) against HCV for screening. Those peptoids that are positive in the screen will then be sequenced, synthesized in bulk, and tested for their ability to block the binding of the native E2 protein of HCV to the screening MAb Those that block at the lowest concentration will be conjugated (together or separately) to a carrier protein, mixed with alum (an adjuvant approved for humans), and used to immunize mice. The mouse sera will be tested for reactivity against E2. Those that react will be further tested for their ability to neutralize a panel of HCV genotypes.
Jobs Summary: N/A (Total jobs reported: 0)
Project Status: Not Started
This award's data was last updated on Sep. 29, 2009. Help expand these official descriptions using the wiki below.